- Home
- CAAP vs BHVN Comparison
CAAP vs BHVN Comparison
Compare CAAP & BHVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CAAP | BHVN |
|---|---|---|
| Founded | 1998 | 2013 |
| Country | Luxembourg | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 1.1B |
| IPO Year | 2018 | 2017 |
Fundamental Metrics
Financial Performance| Metric | CAAP | BHVN |
|---|---|---|
| Price | $26.57 | $11.56 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 16 |
| Target Price | $24.60 | ★ $29.79 |
| AVG Volume (30 Days) | 174.0K | ★ 3.8M |
| Earning Date | 11-24-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.09 | N/A |
| Revenue | ★ $1,872,934,000.00 | N/A |
| Revenue This Year | $3.24 | N/A |
| Revenue Next Year | $9.46 | $2,219.74 |
| P/E Ratio | $23.52 | ★ N/A |
| Revenue Growth | ★ 25.19 | N/A |
| 52 Week Low | $15.01 | $7.48 |
| 52 Week High | $26.97 | $44.28 |
Technical Indicators
Market Signals| Indicator | CAAP | BHVN |
|---|---|---|
| Relative Strength Index (RSI) | 71.98 | 56.95 |
| Support Level | $25.23 | $8.29 |
| Resistance Level | $26.27 | $11.71 |
| Average True Range (ATR) | 0.88 | 0.72 |
| MACD | -0.02 | 0.46 |
| Stochastic Oscillator | 81.79 | 95.03 |
Price Performance
Historical ComparisonAbout CAAP Corporacion America Airports SA
Corporacion America Airports SA acquires, develops, and operates airport concessions. Its operating segments are geographically divided into Argentina, Italy, Brazil, Uruguay, Ecuador, and Armenia. The company generates a majority of its revenue from the Argentina segment. The firm's revenue is categorized into Aeronautical Revenue, Non-Aeronautical Revenue, Commercial Revenue, Construction Service Revenue, and Other Revenue.
About BHVN Biohaven Ltd.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.